1527 related articles for article (PubMed ID: 8600797)
21. Immunohistochemical expression of retinoblastoma protein in cutaneous melanomas.
Saenz-SantamarÃa MC; McNutt NS; Shea CR
Br J Dermatol; 1995 Dec; 133(6):890-5. PubMed ID: 8547040
[TBL] [Abstract][Full Text] [Related]
22. p53 expression in non small cell lung cancer: clinical and biological correlations.
Fontanini G; Bigini D; Vignati S; Macchiarini P; Pepe S; Angeletti CA; Pingitore R; Squartini F
Anticancer Res; 1993; 13(3):737-42. PubMed ID: 8100413
[TBL] [Abstract][Full Text] [Related]
23. A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma.
Clark WH; Elder DE; Guerry D; Epstein MN; Greene MH; Van Horn M
Hum Pathol; 1984 Dec; 15(12):1147-65. PubMed ID: 6500548
[TBL] [Abstract][Full Text] [Related]
24. Loss of expression of protein kinase a regulatory subunit 1alpha in pigmented epithelioid melanocytoma but not in melanoma or other melanocytic lesions.
Zembowicz A; Knoepp SM; Bei T; Stergiopoulos S; Eng C; Mihm MC; Stratakis CA
Am J Surg Pathol; 2007 Nov; 31(11):1764-75. PubMed ID: 18059235
[TBL] [Abstract][Full Text] [Related]
25. Proliferation antigens in cutaneous melanocytic tumors--an immunohistochemical study comparing the transferrin receptor and the Ki 67 antigen.
Soyer HP; Smolle J; Smolle-Juettner FM; Kerl H
Dermatologica; 1989; 179(1):3-9. PubMed ID: 2569990
[TBL] [Abstract][Full Text] [Related]
26. Mutation and expression of the p53 gene in malignant melanoma cell lines.
Weiss J; Schwechheimer K; Cavenee WK; Herlyn M; Arden KC
Int J Cancer; 1993 Jun; 54(4):693-9. PubMed ID: 8514460
[TBL] [Abstract][Full Text] [Related]
27. Expression of melanocyte differentiation antigens and ki-67 in nodal nevi and comparison of ki-67 expression with metastatic melanoma.
Lohmann CM; Iversen K; Jungbluth AA; Berwick M; Busam KJ
Am J Surg Pathol; 2002 Oct; 26(10):1351-7. PubMed ID: 12360050
[TBL] [Abstract][Full Text] [Related]
28. Growth dynamics of acquired melanocytic nevi. Higher reactivity of proliferating cell nuclear antigen in junctional and compound nevi than intradermal nevi.
Tokuda Y; Saida T; Mukai K; Takasaki Y
J Am Acad Dermatol; 1994 Aug; 31(2 Pt 1):220-4. PubMed ID: 7913717
[TBL] [Abstract][Full Text] [Related]
29. The TP53 tumor suppressor gene and melanoma tumorigenesis: is there a relationship?
Hussein MR
Tumour Biol; 2004; 25(4):200-7. PubMed ID: 15557758
[TBL] [Abstract][Full Text] [Related]
30. Expression of mutant p53 in melanoma.
Stretch JR; Gatter KC; Ralfkiaer E; Lane DP; Harris AL
Cancer Res; 1991 Nov; 51(21):5976-9. PubMed ID: 1933861
[TBL] [Abstract][Full Text] [Related]
31. Strategies for improving the immunohistochemical staining of various intranuclear prognostic markers in formalin-paraffin sections: androgen receptor, estrogen receptor, progesterone receptor, p53 protein, proliferating cell nuclear antigen, and Ki-67 antigen revealed by antigen retrieval techniques.
Taylor CR; Shi SR; Chaiwun B; Young L; Imam SA; Cote RJ
Hum Pathol; 1994 Mar; 25(3):263-70. PubMed ID: 7512074
[TBL] [Abstract][Full Text] [Related]
32. Loss of expression of the p16INK4/CDKN2 gene in cutaneous malignant melanoma correlates with tumor cell proliferation and invasive stage.
Talve L; Sauroja I; Collan Y; Punnonen K; Ekfors T
Int J Cancer; 1997 Jun; 74(3):255-9. PubMed ID: 9221801
[TBL] [Abstract][Full Text] [Related]
33. Expression of p53 protein, PCNA, and Ki-67 in osteosarcomas of bone.
Park HR; Park YK
J Korean Med Sci; 1995 Oct; 10(5):360-7. PubMed ID: 8750062
[TBL] [Abstract][Full Text] [Related]
34. Human monoclonal antibodies that distinguish cutaneous malignant melanomas from benign nevi in fixed tissue sections.
Imam A; Mitchell MS; Modlin RL; Taylor CR; Kempf RA; Kan-Mitchell J
J Invest Dermatol; 1986 Feb; 86(2):145-8. PubMed ID: 3528308
[TBL] [Abstract][Full Text] [Related]
35. Malignant melanoma with paradoxical maturation.
Ruhoy SM; Prieto VG; Eliason SL; Grichnik JM; Burchette JL; Shea CR
Am J Surg Pathol; 2000 Dec; 24(12):1600-14. PubMed ID: 11117780
[TBL] [Abstract][Full Text] [Related]
36. Enhanced expression of Ki-67, topoisomerase IIalpha, PCNA, p53 and p21WAF1/Cip1 reflecting proliferation and repair activity in UV-irradiated melanocytic nevi.
Rudolph P; Tronnier M; Menzel R; Möller M; Parwaresch R
Hum Pathol; 1998 Dec; 29(12):1480-7. PubMed ID: 9865836
[TBL] [Abstract][Full Text] [Related]
37. Melanocytic nevi and melanoma: unraveling a complex relationship.
Damsky WE; Bosenberg M
Oncogene; 2017 Oct; 36(42):5771-5792. PubMed ID: 28604751
[TBL] [Abstract][Full Text] [Related]
38. Evaluation of human monoclonal antibody (2-139-1) in cutaneous melanocytic neoplasms in fixed tissue sections.
White WL; Tam ST; Mitchell MS; Yu MC; Kan-Mitchell J
J Histochem Cytochem; 1991 Jun; 39(6):777-85. PubMed ID: 1709658
[TBL] [Abstract][Full Text] [Related]
39. hTERT expression in melanocytic lesions: an immunohistochemical study on paraffin-embedded tissue.
Fullen DR; Zhu W; Thomas D; Su LD
J Cutan Pathol; 2005 Nov; 32(10):680-4. PubMed ID: 16293180
[TBL] [Abstract][Full Text] [Related]
40. [Immunohistochemical analysis of ras gene expression in human melanomas and melanocytic nevi].
Yasuda H
Hokkaido Igaku Zasshi; 1989 May; 64(3):243-53. PubMed ID: 2670726
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
